Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Autolus Forced To Slim Down, But Believes CAR-T Has 'Transformational' Potential

Management Reshuffle And 20% Headcount Cut

Executive Summary

The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.

You may also be interested in...



Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME

Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.

UK Firms Big And Small Benefit From Biotech Bubble

Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.

Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut

Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel